Published in Bone on September 30, 2005
Relationships between fat and bone. Osteoporos Int (2007) 2.51
Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med (2011) 1.95
Determinants of plasma parathyroid hormone levels in young women. Calcif Tissue Int (2010) 1.58
Bone metabolism in obesity and weight loss. Annu Rev Nutr (2012) 1.28
Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). J Bone Miner Res (2014) 1.19
Divergent effects of obesity on fragility fractures. Clin Interv Aging (2014) 1.14
Obesity alters cortical and trabecular bone density and geometry in women. Osteoporos Int (2010) 1.07
Vitamin D insufficiency prior to bariatric surgery: risk factors and a pilot treatment study. Clin Endocrinol (Oxf) (2008) 1.05
Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. J Clin Endocrinol Metab (2012) 1.02
The association of adiposity with parathyroid hormone in healthy older adults. Endocrine (2009) 1.01
Serum 25-hydroxyvitamin D3 and body composition in an elderly cohort from Germany: a cross-sectional study. Nutr Metab (Lond) (2012) 0.95
Demographic, dietary, and serum factors and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporos Int (2011) 0.92
Obesity and fracture risk. Clin Cases Miner Bone Metab (2014) 0.92
Risk factors for nonvertebral fracture in obese older women. J Clin Endocrinol Metab (2011) 0.92
Hormonal and dietary influences on true fractional calcium absorption in women: role of obesity. Osteoporos Int (2012) 0.88
Bone and mineral metabolism in patients undergoing Roux-en-Y gastric bypass. Osteoporos Int (2013) 0.87
The effect of obesity on the relationship between serum parathyroid hormone and 25-hydroxyvitamin D in women. J Clin Endocrinol Metab (2013) 0.80
Influence of morbid obesity on parathyroidectomy outcomes in primary hyperparathyroidism. Am J Surg (2010) 0.78
The high serum monocyte chemoattractant protein-1 in obesity is influenced by high parathyroid hormone and not adiposity. J Clin Endocrinol Metab (2011) 0.78
Discordance between fat mass index and body mass index is associated with reduced bone mineral density in women but not in men: the Busselton Healthy Ageing Study. Osteoporos Int (2016) 0.78
The impact of obesity on the presentation of primary hyperparathyroidism. J Clin Endocrinol Metab (2014) 0.75
Fat and Bone: An Odd Couple. Front Endocrinol (Lausanne) (2016) 0.75
Influence of Vitamin D and Parathyroid Hormone on Bone and Metabolic Risk in Women with Previous Gestational Diabetes. Horm Metab Res (2016) 0.75
Bioavailable 25(OH)D but Not Total 25(OH)D Is an Independent Determinant for Bone Mineral Density in Chinese Postmenopausal Women. EBioMedicine (2016) 0.75
Serum Parathyroid Hormone Responses to Vitamin D Supplementation in Overweight/Obese Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Nutrients (2017) 0.75
The clinical impact of plasma leptin levels in a cohort of chronic kidney disease patients. Clin Kidney J (2012) 0.75
Obesity is a concern for bone health with aging. Nutr Res (2017) 0.75
Parathyroid hormone reflects adiposity and cardiometabolic indices but not bone density in normal men. Bonekey Rep (2016) 0.75
Association of Triglyceride-Related Genetic Variants With Mitral Annular Calcification. J Am Coll Cardiol (2017) 0.75
Renal osteodystrophy in the obesity era: Is metabolic syndrome relevant? PLoS One (2017) 0.75
Body Size and the Risk of Primary Hyperparathyroidism in Women: A Cohort Study. J Bone Miner Res (2017) 0.75
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ (2010) 10.85
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ (2008) 5.14
Paget's disease of bone: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2014) 4.63
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab (2007) 4.01
Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc (2008) 2.75
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74
Factors influencing mortality in acromegaly. J Clin Endocrinol Metab (2004) 2.69
Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. Am J Clin Nutr (2011) 2.44
Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet (2011) 2.34
Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res (2011) 2.07
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
Discrepancies in predicted fracture risk in elderly people. BMJ (2013) 2.04
Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 1.98
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res (2012) 1.92
The effects of seasonal variation of 25-hydroxyvitamin D and fat mass on a diagnosis of vitamin D sufficiency. Am J Clin Nutr (2007) 1.83
Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation (2004) 1.80
Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone (2007) 1.73
Acute coronary syndrome care across Australia and New Zealand: the SNAPSHOT ACS study. Med J Aust (2013) 1.69
Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab (2010) 1.68
Decreased bone density in men on methadone maintenance therapy. Addiction (2010) 1.63
Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial. Bone (2012) 1.62
Goal-directed treatment of osteoporosis. J Bone Miner Res (2013) 1.58
Skeletal phenotype of the leptin receptor-deficient db/db mouse. J Bone Miner Res (2011) 1.55
Pseudonormal mitral filling pattern predicts hospital re-admission in patients with congestive heart failure. J Am Coll Cardiol (2002) 1.55
WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. PLoS Genet (2012) 1.55
Cellular characterization of the gouty tophus: a quantitative analysis. Arthritis Rheum (2010) 1.52
Association of fat-free mass and training status with left ventricular size and mass in endurance-trained athletes. J Am Coll Cardiol (2004) 1.48
Defining vitamin D deficiency. N Z Med J (2007) 1.45
Abdominal aortic calcification on vertebral morphometry images predicts incident myocardial infarction. J Bone Miner Res (2010) 1.45
Should measurement of vitamin D and treatment of vitamin D insufficiency be routine in New Zealand? N Z Med J (2012) 1.42
CLINICAL Review # : low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab (2007) 1.42
The randomised controlled trial to meta-analysis ratio: original data versus systematic reviews in the medical literature. N Z Med J (2007) 1.40
Evaluation of the FRAX and Garvan fracture risk calculators in older women. J Bone Miner Res (2011) 1.39
Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial. J Bone Miner Res (2010) 1.37
Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cells. Arthritis Rheum (2008) 1.36
In vitro and in vivo effects of adiponectin on bone. Endocrinology (2009) 1.35
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res (2011) 1.32
A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet (2002) 1.32
Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab (2005) 1.30
General practitioners' and pharmacists' perceptions of the role of community pharmacists in delivering clinical services. Res Social Adm Pharm (2009) 1.28
Modulation of osteoclastogenesis by fatty acids. Endocrinology (2008) 1.25
beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res (2004) 1.25
Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol (2003) 1.25
In vivo retinal nerve fiber layer thickness measured by optical coherence tomography predicts visual recovery after surgery for parachiasmal tumors. Invest Ophthalmol Vis Sci (2008) 1.24
Pathogenesis and management of Paget's disease of bone. Lancet (2008) 1.21
10-year probability of recurrent fractures following wrist and other osteoporotic fractures in a large clinical cohort: an analysis from the Manitoba Bone Density Program. Arch Intern Med (2008) 1.20
Three-dimensional assessment of left ventricular systolic strain in patients with type 2 diabetes mellitus, diastolic dysfunction, and normal ejection fraction. Am J Cardiol (2004) 1.18
The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2015) 1.18
Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. Hum Mol Genet (2013) 1.17
Vitamin D insufficiency and health outcomes over 5 y in older women. Am J Clin Nutr (2009) 1.17
Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab (2004) 1.16
Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res (2007) 1.16
The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab (2008) 1.14
Age-, gender-, and weight-related effects on levels of 25-hydroxyvitamin D are not mediated by vitamin D binding protein. Clin Endocrinol (Oxf) (2007) 1.12
Calcium supplements increase risk of myocardial infarction. J Bone Miner Res (2015) 1.11
Macular thickness predictive of visual field sensitivity in ischaemic optic neuropathy. Acta Ophthalmol (2012) 1.09
Determinants of vitamin D status in older women living in a subtropical climate. Osteoporos Int (2005) 1.08
Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. Clin Endocrinol (Oxf) (2007) 1.08